Mia Wadelius

Mia Wadelius is a Professor at the Department of Medical Sciences specializing in Clinical Pharmacogenomics and Osteoporosis at Uppsala University. With an MD qualification, she has established herself as a leading researcher in pharmacogenomics and clinical pharmacology, focusing on how genetic variations affect drug responses and adverse reactions.

Her research interests span multiple critical areas in personalized medicine, including:

• Pharmacogenomics of anticoagulant therapy, particularly warfarin dosing
• Genetic associations with drug-induced adverse reactions
• Pharmacovigilance and risk prediction for adverse drug events
• Genetic factors influencing drug metabolism and response
• Precision medicine applications in clinical practice

Professor Wadelius's extensive publication record demonstrates her leadership in pharmacogenomics research. Her recent work has focused on vaccine-related adverse events, anticoagulant therapy, chemotherapy toxicity in pediatric oncology, and genetic factors in drug-induced liver injury. Her research employs advanced genomic techniques including genome-wide association studies (GWAS), whole genome sequencing, and meta-analyses to identify genetic variants associated with drug responses.

Her scientific contributions include numerous high-impact publications in journals such as npj Vaccines, European Journal of Clinical Pharmacology, and Scandinavian Journal of Immunology. Her work has significantly advanced our understanding of how genetic factors influence individual responses to medications, paving the way for more personalized and safer drug therapies.

Professor Wadelius has been instrumental in developing pharmacogenetic guidelines and has contributed to major collaborative research efforts in pharmacogenomics. Her work bridges basic genetic research with clinical applications, aiming to translate genomic discoveries into improved patient care and medication safety.